- Article
- Source: Campus Sanofi
T1 Edition Junior Study
Edition Junior
Download this clinical summary to read about the benefits of Toujeo® Insulin Glargine 300U/ml in children and adolescents from the age of 6 years in this randomised trial. Edition Junior was a 6 month long, open-label, double arm, parallel group, non-inferiority study in 463 children with T1DM. The aim of the study was to demonstrate non-inferiority of Toujeo® vs insulin glargine 100 U/mL from baseline to Week 26.
Our Products
entry-site-modal-text
Welcome to Sanofi Campus Ireland
This site is intended for Healthcare Professionals in the Republic of Ireland and contains information on Sanofi Ireland medicine, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a Healthcare Professional in the Republic of Ireland. This site contains promotional information.
MAT-IE-2300185 (v4.0)
Date of Preparation: June 2024